WO2003069332A3 - Detection and/or monitoring of synuclein-related diseases - Google Patents
Detection and/or monitoring of synuclein-related diseases Download PDFInfo
- Publication number
- WO2003069332A3 WO2003069332A3 PCT/GB2003/000677 GB0300677W WO03069332A3 WO 2003069332 A3 WO2003069332 A3 WO 2003069332A3 GB 0300677 W GB0300677 W GB 0300677W WO 03069332 A3 WO03069332 A3 WO 03069332A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- synuclein
- monitoring
- detection
- related diseases
- patient
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2480466A CA2480466C (en) | 2002-02-14 | 2003-02-14 | Detection and/or monitoring of synuclein-related diseases |
JP2003568402A JP2005528588A (en) | 2002-02-14 | 2003-02-14 | Detection and / or monitoring of synuclein-related diseases |
AT03709934T ATE442592T1 (en) | 2002-02-14 | 2003-02-14 | DETECTION AND/OR MONITORING OF SYNUCLEIN-ASSOCIATED DISEASES |
EP03709934.8A EP1476758B2 (en) | 2002-02-14 | 2003-02-14 | Detection and/or monitoring of synuclein-related diseases |
US10/503,416 US20050176078A1 (en) | 2002-02-14 | 2003-02-14 | Detection and/or monitoring of synuclein-related diseases |
DE60329165T DE60329165D1 (en) | 2002-02-14 | 2003-02-14 | DETECTION AND / OR OBSERVATION OF SYNUCLEIN ASSOCIATED DISEASES |
AU2003214364A AU2003214364A1 (en) | 2002-02-14 | 2003-02-14 | Detection and/or monitoring of synuclein-related diseases |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0203446.0 | 2002-02-14 | ||
GBGB0203446.0A GB0203446D0 (en) | 2002-02-14 | 2002-02-14 | Detection and/or monitoring of synuclein-related diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003069332A2 WO2003069332A2 (en) | 2003-08-21 |
WO2003069332A3 true WO2003069332A3 (en) | 2004-01-08 |
Family
ID=9931023
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2003/000677 WO2003069332A2 (en) | 2002-02-14 | 2003-02-14 | Detection and/or monitoring of synuclein-related diseases |
Country Status (9)
Country | Link |
---|---|
US (1) | US20050176078A1 (en) |
EP (1) | EP1476758B2 (en) |
JP (1) | JP2005528588A (en) |
AT (1) | ATE442592T1 (en) |
AU (1) | AU2003214364A1 (en) |
CA (1) | CA2480466C (en) |
DE (1) | DE60329165D1 (en) |
GB (1) | GB0203446D0 (en) |
WO (1) | WO2003069332A2 (en) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040146521A1 (en) * | 1999-06-01 | 2004-07-29 | Schenk Dale B. | Prevention and treatment of synucleinopathic disease |
US9034337B2 (en) | 2003-10-31 | 2015-05-19 | Prothena Biosciences Limited | Treatment and delay of outset of synucleinopathic and amyloidogenic disease |
US20080014194A1 (en) * | 2003-10-31 | 2008-01-17 | Elan Pharmaceuticals, Inc. | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease |
US8506959B2 (en) * | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
TW200509968A (en) * | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
US8697082B2 (en) * | 2002-11-01 | 2014-04-15 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
US7358331B2 (en) * | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
US7674599B2 (en) * | 2003-11-08 | 2010-03-09 | Elan Pharmaceuticals, Inc. | Methods of using antibodies to detect alpha-synuclein in fluid samples |
DE10361258A1 (en) | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Use of substituted 2-aminotetralins for the preventive treatment of Parkinson's disease |
DE102004014841B4 (en) | 2004-03-24 | 2006-07-06 | Schwarz Pharma Ag | Use of rotigotine for the treatment and prevention of Parkinson-Plus syndrome |
ES2310057B1 (en) * | 2004-07-19 | 2009-11-17 | Oryzon Genomics, S.A. | METHOD OF MOLECULAR ANALYSIS AND TREATMENT IN DEMENTIA OF LEWY BODIES. |
CN1752104B (en) * | 2004-09-21 | 2010-05-05 | 北京市肿瘤防治研究所 | Monoclonal antibody of synapse protein gamma and its application |
WO2007011907A2 (en) * | 2005-07-19 | 2007-01-25 | University Of Rochester | Alpha-synuclein antibodies and methods related thereto |
IL199534A (en) | 2007-01-05 | 2013-01-31 | Univ Zuerich | Isolated human antibody which is capable of selectively recognizing a neoepitope of a disorder-associated protein, a polynucleotide encoding the antibody, a vector comprising the polynucleotide, a host cell comprising the polynucleotide or the vector, a composition comprising the antibody and methods and uses associated therewith |
US8147833B2 (en) * | 2007-02-23 | 2012-04-03 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
EP2118300B1 (en) * | 2007-02-23 | 2015-05-27 | Prothena Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
GB0716885D0 (en) | 2007-08-30 | 2007-10-10 | United Arab Emirates Universit | Diagnostic agent |
JP5810413B2 (en) | 2008-12-19 | 2015-11-11 | バイオジェン インターナショナル ニューロサイエンス ゲーエムベーハー | Human anti-alpha synuclein autoantibodies |
WO2011033252A1 (en) * | 2009-09-16 | 2011-03-24 | United Arab Emirates University | Diagnostic agent for parkinson's disease |
CN101692092B (en) * | 2009-09-24 | 2013-04-10 | 首都医科大学宣武医院 | Method for quantitatively detecting alpha-synuclein auto-antibodies in human sera |
US10989718B2 (en) * | 2014-09-11 | 2021-04-27 | Amprion, Inc. | Detection of misfolded alpha synuclein protein |
WO2012061789A2 (en) * | 2010-11-05 | 2012-05-10 | Brandeis University | Tetrameric alpha-synuclein and use thereof |
WO2012061786A1 (en) * | 2010-11-05 | 2012-05-10 | Brandeis University | Ice cleaved alpha-synuclein a biomarker |
WO2012074882A2 (en) * | 2010-11-24 | 2012-06-07 | Elan Pharmaceuticals, Inc. | Phagocytic activity as a marker of synucleinopathic disease |
WO2012177972A1 (en) | 2011-06-23 | 2012-12-27 | Biogen Idec International Neuroscience Gmbh | Anti-alpha synuclein binding molecules |
JP6263473B2 (en) * | 2011-11-02 | 2018-01-31 | バイオジェン インターナショナル ニューロサイエンス ゲーエムベーハー | Use of anti-α-synuclein antibodies to diagnose high levels of α-synuclein in the brain |
ES2481517B1 (en) * | 2013-01-29 | 2015-06-01 | Universidad De Sevilla | Method for the diagnosis of parkinson's disease in early stages |
HRP20231232T1 (en) * | 2014-09-11 | 2024-01-19 | Board Of Regents Of The University Of Texas System | Detection of misfolded proteins |
WO2016075516A1 (en) | 2014-11-14 | 2016-05-19 | United Arab Emirates University | Compounds for use as imaging agents |
MA41115A (en) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | ALZHEIMER'S DISEASE TREATMENT PROCESS |
CN104711280B (en) * | 2014-12-10 | 2018-04-13 | 中国医学科学院医学生物学研究所 | The method that expression and purifying lack exon 3 and 5 α synapse nucleoprotein alternative splicing body proteins at the same time |
MX2019013589A (en) | 2017-05-16 | 2020-07-20 | Claudio Soto Jara | Detection of misfolded tau protein. |
IL271359B2 (en) * | 2017-06-19 | 2023-11-01 | Kainos Medicine Inc | Modulators of alpha-synuclein |
SG11202001281WA (en) | 2017-08-22 | 2020-03-30 | Biogen Ma Inc | Pharmaceutical compositions containing anti-beta amyloid antibodies |
JP7173532B2 (en) * | 2018-08-28 | 2022-11-16 | 学校法人順天堂 | Diagnosis of α-Synucleinopathy |
RU2703430C1 (en) * | 2018-12-13 | 2019-10-16 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр глазных болезней имени Гельмгольца" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ ГБ им. Гельмгольца" Минздрава России) | Method for prediction of developing neurodegenerative diseases, underlying the pathogenesis of which is gamma-synucleinopathy |
EP3779448A1 (en) * | 2019-08-12 | 2021-02-17 | Baden-Württemberg Stiftung gGmbH | Novel diagnostic marker for creutzfeldt-jakob disease and alzheimer's disease |
EP4111197A1 (en) * | 2020-02-25 | 2023-01-04 | Markus Otto | Diagnosing a disease associated with synaptic degeneration using an elisa for determining a beta-synuclein concentration in csf |
EP4252243A2 (en) | 2020-11-30 | 2023-10-04 | Enigma Biointelligence, Inc. | Non-invasive assessment of alzheimer's disease |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999050300A1 (en) * | 1998-03-30 | 1999-10-07 | The Trustees Of The University Of Pennsylvania | Method of identifying, diagnosing and treating synuclein positive neurodegenerative disorders |
WO2000002053A2 (en) * | 1998-07-03 | 2000-01-13 | Innogenetics N.V. | Differential diagnosis of neurodegeneration |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5602042A (en) * | 1994-04-14 | 1997-02-11 | Cytyc Corporation | Method and apparatus for magnetically separating biological particles from a mixture |
JP2004502781A (en) * | 2000-07-07 | 2004-01-29 | パナシア ファーマシューティカルズ インコーポレーテッド | Methods for preventing damage to nervous tissue and treating α-synuclein disease |
AU2002239765A1 (en) * | 2000-11-03 | 2002-06-03 | Proteotech, Inc. | Antibody pti-hs7 for treatment of alzheimer's disease and other amyloidoses and parkinson's disease |
-
2002
- 2002-02-14 GB GBGB0203446.0A patent/GB0203446D0/en not_active Ceased
-
2003
- 2003-02-14 DE DE60329165T patent/DE60329165D1/en not_active Expired - Lifetime
- 2003-02-14 CA CA2480466A patent/CA2480466C/en not_active Expired - Fee Related
- 2003-02-14 AT AT03709934T patent/ATE442592T1/en not_active IP Right Cessation
- 2003-02-14 JP JP2003568402A patent/JP2005528588A/en active Pending
- 2003-02-14 US US10/503,416 patent/US20050176078A1/en not_active Abandoned
- 2003-02-14 WO PCT/GB2003/000677 patent/WO2003069332A2/en active Application Filing
- 2003-02-14 EP EP03709934.8A patent/EP1476758B2/en not_active Expired - Lifetime
- 2003-02-14 AU AU2003214364A patent/AU2003214364A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999050300A1 (en) * | 1998-03-30 | 1999-10-07 | The Trustees Of The University Of Pennsylvania | Method of identifying, diagnosing and treating synuclein positive neurodegenerative disorders |
WO2000002053A2 (en) * | 1998-07-03 | 2000-01-13 | Innogenetics N.V. | Differential diagnosis of neurodegeneration |
Non-Patent Citations (3)
Title |
---|
EL-AGNAF OMAR M A ET AL: "Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma.", THE FASEB JOURNAL: OFFICIAL PUBLICATION OF THE FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY. UNITED STATES OCT 2003, vol. 17, no. 13, October 2003 (2003-10-01), pages 1945 - 1947, XP002258024, ISSN: 1530-6860 * |
JIA TONGLI ET AL: "Stimulation of breast cancer invasion and metastasis by synuclein gamma", CANCER RESEARCH, vol. 59, no. 3, 1 February 1999 (1999-02-01), pages 742 - 747, XP002258023, ISSN: 0008-5472 * |
KIM S H ET AL: "Characterization of alpha-synuclein in human lymphocytes", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 27, no. 1, 2001, 31st Annual Meeting of the Society for Neuroscience;San Diego, California, USA; November 10-15, 2001, pages 862, XP001155386, ISSN: 0190-5295 * |
Also Published As
Publication number | Publication date |
---|---|
GB0203446D0 (en) | 2002-04-03 |
DE60329165D1 (en) | 2009-10-22 |
ATE442592T1 (en) | 2009-09-15 |
EP1476758B2 (en) | 2015-02-11 |
JP2005528588A (en) | 2005-09-22 |
EP1476758B1 (en) | 2009-09-09 |
AU2003214364A1 (en) | 2003-09-04 |
WO2003069332A2 (en) | 2003-08-21 |
CA2480466C (en) | 2010-12-21 |
EP1476758A2 (en) | 2004-11-17 |
US20050176078A1 (en) | 2005-08-11 |
CA2480466A1 (en) | 2003-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003069332A3 (en) | Detection and/or monitoring of synuclein-related diseases | |
WO2006086442A3 (en) | Method of detecting abnormal tissue | |
AU2002327308A1 (en) | Methods for evaluating pathologic conditions using extracellular rna | |
WO2002018652A3 (en) | Method for detection of htr and htert telomerase-associated rna in plasma or serum | |
IL148795A0 (en) | Apparatus and method for monitoring tissue vitality parameters for the diagnosis of body metabolic emergency state | |
EP1534115A4 (en) | Body surface probe, apparatus and method for non-invasively detecting medical conditions | |
AU2003272064A8 (en) | System for monitoring the health of an individual and method for use thereof | |
WO2005028029A3 (en) | Patient monitoring, diagnosis, and/or therapy systems and methods | |
WO2004008147A3 (en) | Diagnosis and prevention of cancer cell invasion | |
AU2003212608A1 (en) | System and method for assessing and indicating the health of components | |
HK1070575A1 (en) | Use of botulinum toxin for treating cardiovasculardiseases | |
WO2007086986A3 (en) | Novel application of biosensors for diagnosis and treatment of disease | |
WO2008030616A3 (en) | Monitoring cancer stem cells | |
EP1310797A3 (en) | Method of monitoring neuroprotective treatment | |
WO2007079146A8 (en) | Treatment for non-hodgkin's lymphoma | |
AU2003253014A8 (en) | Method for the diagnosis and differential diagnosis of neurological diseases | |
IL174127A0 (en) | Apparatus for, and method of, determining the condition of a patient's heart | |
EP1774029A4 (en) | Method for detecting the risk of and for treatment of type 2 diabetes | |
WO2005089310A3 (en) | Breath test for oral malodor | |
AU2002342893A1 (en) | Method and apparatus for monitoring a technical installation, especially for carrying out diagnosis | |
WO2006047475A3 (en) | Detection and analysis of ophthalmically-relevant fluorescent molecules | |
WO2002095358A3 (en) | System and method for monitoring or treating a health condition | |
WO2006094068A3 (en) | Hdac inhibitors that promote brm expression and brm related diagnostics | |
WO2004045376A3 (en) | Screening methods to identify treatments for autoimmune disease | |
WO2005048927A3 (en) | Methods and reagents for the treatment of inflammatory disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003568402 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003709934 Country of ref document: EP Ref document number: 2003214364 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200407371 Country of ref document: ZA Ref document number: 535313 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2480466 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 2003709934 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10503416 Country of ref document: US |